Ladenburg lowered the firm’s price target on Eyenovia to $10 from $15 and keeps a Buy rating on the shares. The reduced price target is based on updated estimates associated with the rollout of MydCombi and Clobetasol, and does not include MicroLine, which is potential upside to the valuation, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EYEN:
- Eyenovia congratulates Formosa Pharmaceuticals on FDA approval
- Eyenovia announces FDA approval of Redwood City as manufacturing facility
- Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
- Eyenovia Unveils Optejet Platform Progress and Pipeline
- Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada
